DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Phase 1

Terminated

Conditions: Burkitt Lymphoma
CD20-Positive Neoplastic Cells Present
Indolent Non-Hodgkin Lymphoma
Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Clearing Agent
Drug: Cytarabine
Drug: Etoposide
Radiation: Indium In 111-DOTA-Biotin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Yttrium Y 90-DOTA-Biotin

First Posted Date: 2015-06-26

Last Posted Date: 2020-11-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT02483000

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors

Not Applicable

Completed

Conditions: Endometrial Cancer

Interventions: Behavioral: Enhanced Usual Care Group (Arm C)
Behavioral: Telemedicine Weight Management plus Wi-Fi Scale (Arm A)
Behavioral: Text for Diet (Text4Diet) Group (Arm B)

First Posted Date: 2015-06-09

Last Posted Date: 2016-06-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 207

Registration Number: NCT02466061

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Washington University in St Louis (Siteman Cancer Center), St. Louis, Missouri, United States

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Adenocarcinoma
Stage IIA Prostate Cancer AJCC v7
Stage I Prostate Cancer AJCC V7

Interventions: Behavioral: Behavioral Dietary Intervention
Other: Informational Intervention
Behavioral: Exercise Intervention
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2015-05-27

Last Posted Date: 2023-01-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 117

Registration Number: NCT02454517

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Women's Health Initiative Strong and Healthy Study

Not Applicable

Completed

Conditions: Cardiovascular Mortality
Peripheral Artery Disease
Depressive Symptoms
Mortality
Stroke
Clinical (Non-hip) Fractures
Myocardial Infarction
Hip Fractures
Coronary Revascularization
Falls

Interventions: Behavioral: Physical Activity

First Posted Date: 2015-04-24

Last Posted Date: 2025-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 49331

Registration Number: NCT02425345

Telephone-Delivered Interventions for Smoking Cessation

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Telephone Delivered Intervention

First Posted Date: 2015-04-21

Last Posted Date: 2020-01-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1275

Registration Number: NCT02421991

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Phase 1

Terminated

Conditions: Stage IV Non-Small Cell Lung Cancer AJCC v7
Stage IV Pleural Malignant Mesothelioma AJCC v7
WT1 Positive
Advanced Pleural Malignant Mesothelioma
HLA-A*0201 Positive Cells Present
Recurrent Non-Small Cell Lung Carcinoma
Stage III Pleural Malignant Mesothelioma AJCC v7
Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Recurrent Pleural Malignant Mesothelioma
Stage III Non-Small Cell Lung Cancer AJCC v7

Interventions: Biological: Aldesleukin
Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2015-04-03

Last Posted Date: 2021-09-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT02408016

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

theFRESHstudy: FRequency of Eating and Its Influence on Satiety and Health

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: High Eating Frequency
Behavioral: Low Eating Frequency

First Posted Date: 2015-03-19

Last Posted Date: 2019-07-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT02392897

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Phase 1

Withdrawn

Conditions: HIV Infection
AIDS-Related Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
AIDS-Related Non-Hodgkin Lymphoma
Recurrent Non-Hodgkin Lymphoma

Interventions: Biological: Gene-Modified HIV-Protected Hematopoietic Stem Cells
Other: Laboratory Biomarker Analysis
Other: Transplant Conditioning

First Posted Date: 2015-03-04

Last Posted Date: 2018-12-27

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02378922

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Phase 1

Withdrawn

Conditions: Human Immunodeficiency Virus 1 Positive
Stage I Adult Hodgkin Lymphoma
Stage I Adult Non-Hodgkin Lymphoma
Stage II Adult Hodgkin Lymphoma
Stage II Adult Non-Hodgkin Lymphoma
Stage III Adult Hodgkin Lymphoma
Stage III Adult Non-Hodgkin Lymphoma
Stage IV Adult Hodgkin Lymphoma
Stage IV Adult Non-Hodgkin Lymphoma

Interventions: Biological: C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs
Drug: Carmustine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
Drug: Plerixafor

First Posted Date: 2015-01-22

Last Posted Date: 2018-11-20

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02343666

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Colombian Screening Mammography Project

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Opportunistic Breast cancer screening
Other: Usual Care

First Posted Date: 2015-01-13

Last Posted Date: 2015-01-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15855

Registration Number: NCT02337582

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy